Physician profile
Dean A Earp
NPI 1669420204
$2,823.78
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $186 · 2021: $26.66 · 2022: $67.00 · 2023: $15.81 · 2024: $67.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $395.61 | 2019-2020 | |
| Novo Nordisk INC | $343.53 | 2019-2024 | Wegovy |
| Allergan, INC. | $221.49 | 2019-2020 | |
| Lilly USA, LLC | $203.08 | 2019 | |
| Horizon Therapeutics Plc | $199.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $182.65 | 2019 | |
| Amgen INC. | $153.15 | 2019-2020 | |
| Abbvie INC. | $119.69 | 2019 | |
| Gilead Sciences, INC. | $77.28 | 2019-2020 | |
| Abbott Laboratories | $76.59 | 2022-2024 | Freestyle Libre 3, Assurity |
| Glaxosmithkline, LLC. | $71.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $69.92 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.62 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.84 | 2019 | |
| Aytu Biopharma, INC. | $63.25 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $58.90 | 2019 | |
| Antares Pharma, INC. | $56.39 | 2019 | |
| Neuronetics, INC. | $52.73 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $48.85 | 2019 | |
| Merck Sharp & Dohme LLC | $37.19 | 2019 | |
| Eisai INC. | $28.09 | 2019 | |
| Nevro Corp. | $26.66 | 2021 | |
| Zyla Life Sciences, INC. | $26.63 | 2019 | |
| Shire North American Group INC | $25.66 | 2019 | |
| Roche Diagnostics Corporation | $22.01 | 2020 | |
| Ironshore Pharmaceuticals INC. | $21.68 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.22 | 2019 | |
| Amarin Pharma, INC. | $18.12 | 2019 | |
| Acclarent, INC | $16.39 | 2019 | |
| Strongbridge US INC. | $13.39 | 2019 | |
| Endo Pharmaceuticals INC. | $12.68 | 2020 | |
| Pfizer INC. | $12.30 | 2019 | |
| Hikma Pharmaceuticals USA | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Earp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.